keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer bone metastases

keyword
https://www.readbyqxmd.com/read/29780354/targeting-the-metastatic-bone-microenvironment-by-micrornas
#1
REVIEW
Marie-Therese Haider, Hanna Taipaleenmäki
Bone metastases are a common and devastating feature of late-stage breast cancer. Metastatic bone disease is a consequence of disturbed bone remodeling due to pathological interactions between cancer cells and the bone microenvironment (BME). In the BME, breast cancer cells severely alter the balanced bone formation and bone resorption driven by osteoblasts and osteoclasts. The complex cellular cross talk in the BME is governed by secreted molecules, signaling pathways and epigenetic cues including non-coding RNAs...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29777404/randomized-trial-comparing-resection-of-primary-tumor-with-no-surgery-in-stage-iv-breast-cancer-at-presentation-protocol-mf07-01
#2
Atilla Soran, Vahit Ozmen, Serdar Ozbas, Hasan Karanlik, Mahmut Muslumanoglu, Abdullah Igci, Zafer Canturk, Zafer Utkan, Cihangir Ozaslan, Turkkan Evrensel, Cihan Uras, Erol Aksaz, Aykut Soyder, Umit Ugurlu, Cavit Col, Neslihan Cabioglu, Betül Bozkurt, Ali Uzunkoy, Neset Koksal, Bahadir M Gulluoglu, Bulent Unal, Can Atalay, Emin Yıldırım, Ergun Erdem, Semra Salimoglu, Atakan Sezer, Ayhan Koyuncu, Gunay Gurleyik, Haluk Alagol, Nalan Ulufi, Uğur Berberoglu, Mustafa Dulger, Omer Cengiz, Efe Sezgin, Ronald Johnson
BACKGROUND: The MF07-01 trial is a multicenter, phase III, randomized, controlled study comparing locoregional treatment (LRT) followed by systemic therapy (ST) with ST alone for treatment-naïve stage IV breast cancer (BC) patients. METHODS: At initial diagnosis, patients were randomized 1:1 to either the LRT or ST group. All the patients were given ST either immediately after randomization or after surgical resection of the intact primary tumor. RESULTS: The trial enrolled 274 patients: 138 in the LRT group and 136 in the ST group...
May 17, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29775160/site-specific-expression-of-amine-oxidases-in-breast-cancer-metastases
#3
Yoon Jin Cha, Woo Hee Jung, Ja Seung Koo
We aimed to evaluate the expression of amine oxidase-related proteins in metastatic breast cancer tissue and determine its clinical implication. A tissue microarray was constructed from a total of 126 metastatic breast tumors (31 bone metastases (24.6%), 36 brain metastases (28.6%), 11 liver metastases (8.7%), and 48 lung metastases (38.1%)). Immunohistochemical staining for amine oxidase-related proteins (lysyl oxidase, diamine oxidase, and monoamine oxidase A and B) was performed. In metastatic breast cancer tissue, lysyl oxidase ( p = 0...
May 2018: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29760166/the-role-of-il-1b-in-breast-cancer-bone-metastasis
#4
Claudia Tulotta, Penelope Dawn Ottewell
Approximately 75% of patients with late stage breast cancer will develop bone metastasis. This condition is currently considered incurable and patients' life expectancy is limited to 2-3 years following diagnosis of bone involvement. IL-1B is a pro-inflammatory cytokine whose expression in primary tumours has been identified as a potential biomarker for predicting breast cancer patients at increased risk for developing bone metastasis. In this Review, we discuss how IL-1B from both the tumour cells and the tumour microenvironment influence growth of primary breast tumours, dissemination into the bone metastatic niche and proliferation into overt metastases...
May 14, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29753718/early-tgf-%C3%AE-inhibition-in-mice-reduces-the-incidence-of-breast-cancer-induced-bone-disease-in-a-myeloid-dependent-manner
#5
Denise Buenrostro, Kristin A Kwakwa, Nicole E Putnam, Alyssa R Merkel, Joshua R Johnson, James E Cassat, Julie A Sterling
The tumor-cell microenvironment is recognized as a dynamic place where critical cell interactions occur and play an important role in altering tumorigenesis. While many studies have investigated the effects of cellular cross-talk within distinct tumor microenvironments, these interactions have yet to be fully examined in bone. It is well-established that many common cancers metastasize to bone, resulting in the development of tumor-induced bone disease (TIBD), a multi-facetted illness that is driven by complex cell interactions within the bone marrow...
May 10, 2018: Bone
https://www.readbyqxmd.com/read/29748233/prospective-study-of-serial-18-f-fdg-pet-and-18-f-fluoride-18-f-naf-pet-to-predict-time-to-skeletal-related-events-time-to-progression-and-survival-in-patients-with-bone-dominant-metastatic-breast-cancer
#6
Lanell M Peterson, Janet O'Sullivan, Qian Vicky Wu, Alena Novakova-Jiresova, Isaac Jenkins, Jean H Lee, Andrew Shields, Susan Montgomery, Hannah M Linden, Julie R Gralow, Vijayakrishna K Gadi, Mark Muzi, Paul E Kinahan, David A Mankoff, Jennifer M Specht
Assessing therapy response of breast cancer bone metastases is challenging. In retrospective studies, serial 18 F-FDG PET was predictive of time to skeletal related events (tSRE) and time-to-progression (TTP). 18 F-NaF PET improves bone metastasis detection compared to bone scans. We prospectively tested 18 F-FDG PET and 18 F-NaF PET to predict tSRE, TTP, and overall survival (OS) in patients with bone-dominant metastatic breast cancer (BD MBC). Methods: Patients with BD MBC were imaged with 18 F-FDG PET and 18 F-NaF PET prior to starting new therapy (scan1) and again at a range of times centered around approximately 4 months later (scan2)...
May 10, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29743027/quantification-of-fdg-pet-ct-with-delayed-imaging-in-patients-with-newly-diagnosed-recurrent-breast-cancer
#7
Christina Baun, Kirsten Falch, Oke Gerke, Jeanette Hansen, Tram Nguyen, Abass Alavi, Poul-Flemming Høilund-Carlsen, Malene G Hildebrandt
BACKGROUND: Several studies have shown the advantage of delayed-time-point imaging with 18F-FDG-PET/CT to distinguish malignant from benign uptake. This may be relevant in cancer diseases with low metabolism, such as breast cancer. We aimed at examining the change in SUV from 1 h (1h) to 3 h (3h) time-point imaging in local and distant lesions in patients with recurrent breast cancer. Furthermore, we investigated the effect of partial volume correction in the different types of metastases, using semi-automatic quantitative software (ROVER™)...
May 9, 2018: BMC Medical Imaging
https://www.readbyqxmd.com/read/29721471/practical-consensus-recommendaton-for-adjuvant-bone-modifying-agents-in-breast-cancer
#8
A Bharatuar, M Kar, S Khatri, V Goswami, R Sarin, S Dawood, R Iyenger, M Ganvir, Purvish M Parikh, S Aggarwal, Vineet Talwar
Bone-modifying therapy is a primary research interest in breast cancer. Several features contribute to the importance of the bone environment in the management of breast cancer. Firstly, bone metastases represent the most common site of breast cancer metastases and secondly, the emergence of cancer treatment-induced bone loss (CTIBL) among breast cancer survivors and patients is of increasing concern. In the adjuvant setting, bisphosphonates can be given to prevent and treat tumor therapy-induced bone loss in premenopausal and postmenopausal women and, owing to their beneficial effect on bone turnover, have also been evaluated for prevention of bone metastases occurrence...
April 2018: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/29720242/anorectal-metastasis-from-breast-carcinoma-a-case-report-and-review-of-the-literature
#9
Hannes Ruymbeke, Luc Harlet, Barbara Stragier, Edwin Steenkiste, Merijn Ryckx, Francois Marolleau
BACKGROUND: Gastrointestinal metastasis from primary breast carcinoma is uncommon, anorectal involvement is extremely rare. CASE PRESENTATION: We present the case of a 65-year old woman who underwent treatment for an infiltrative lobular carcinoma of the left breast with bone metastases and who developed metastasis of the rectum and anal canal 4 years later. CONCLUSIONS: A patient with a history of breast cancer, especially lobular carcinoma, presenting with anorectal symptoms, should raise the suspicion of metastatic disease...
May 2, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29719487/ra223-in-bone-metastases-with-osteolytic-activity
#10
Renato Patrizio Costa, Davide Cardile, Alessandra Murabito, Vincenzo Tripoli, Francesco Verderame
Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223. The evaluation of the deposit areas of Ra223 showed a perfect overlap with the regions of osteolysis previously detected by scintigraphy, indicating a possible therapeutic effect...
April 2018: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29706824/late-breast-cancer-recurrence-with-bone-marrow-metastases-and-acute-pulmonary-hypertension
#11
Dinesh Atwal, Jeanette M Ramos, Issam Makhoul
Bone marrow is one of the most common sites of metastasis from breast cancer. Micrometastases to the bone marrow usually evade the systemic therapies used for the treatment of cancer and eventually lead to relapse later in the course of the illness. We report here a unique case of parallel progression of these bone marrow metastases in a patient with breast cancer who had a relapse a few years after treatment of her primary breast cancer, and she presented with diffuse marrow involvement and pulmonary hypertension without any definitive metastases elsewhere...
April 2018: Proceedings of the Baylor University Medical Center
https://www.readbyqxmd.com/read/29700305/the-therapeutic-effect-of-mir-125b-is-enhanced-by-the-prostaglandin-endoperoxide-synthase-2-cyclooxygenase-2-blockade-and-hampers-ets1-in-the-context-of-the-microenvironment-of-bone-metastasis
#12
Paola Maroni, Paola Bendinelli, Emanuela Matteucci, Maria Alfonsina Desiderio
Bone is the most common site for breast cancer spread. In the pro-metastatic cell line 1833, derived from MDA-MB-231 breast adenocarcinoma cells, both hypoxia and hepatocyte growth factor (HGF) influence the effect of miR-125b on ETS proto-oncogene 1 transcription factor (ETS1). The effect of hypoxia inducible factor 1 alpha subunit (HIF1A), known to promote metastatic spread by upregulating prostaglandin endoperoxide synthase 2 (PTGS2), may be dampened by miR-125b targeting PTGS2. Here, we investigated whether miR-125b plays a role in breast cancer metastasis by measuring its activity in response to the chemotherapeutic agent NS-398 in a xenograft model...
April 27, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29680193/phase-ii-study-of-paclitaxel-and-dasatinib-in-metastatic-breast-cancer
#13
Patrick G Morris, Selene Rota, Karen Cadoo, Stephen Zamora, Sujata Patil, Gabriella D'Andrea, Theresa Gilewski, Jacqueline Bromberg, Chau Dang, Maura Dickler, Shanu Modi, Andrew D Seidman, Nancy Sklarin, Larry Norton, Clifford A Hudis, Monica N Fornier
BACKGROUND: Overexpression and activation of tyrosine kinase Src has been linked to breast carcinogenesis and bone metastases. We showed the feasibility of combining the SRC inhibitor dasatinib with weekly paclitaxel in patients with metastatic breast cancer (MBC) and herein report the subsequent phase II trial. PATIENTS AND METHODS: Patients had received ≤ 2 chemotherapy regimens for measurable, HER2-negative MBC. Patients received paclitaxel and dasatinib (120 mg daily) and were assessed according to Response Evaluation Criteria in Solid Tumors for overall response rate (ORR), the primary end point...
March 15, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29675790/patterns-of-breast-cancer-relapse-in-accordance-to-biological-subtype
#14
Atanas Ignatov, Holm Eggemann, Elke Burger, Tanja Ignatov
PURPOSE: To evaluate the pattern of recurrence of breast cancer according to its biological subtype in a large cohort of patients treated with therapy representative of current practice. PATIENTS AND METHODS: Patients treated between 2000 and 2016 with known biological subtype were eligible. Data were prospectively collected. Primary endpoint was the subtype-dependent pattern and time of recurrence. Loco-regional and distant site and time of recurrence were assessed...
April 19, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29667006/establishment-and-characterization-of-a-c57bl-6-mouse-model-of-bone-metastasis-of-breast-cancer
#15
Toru Hiraga, Tadashi Ninomiya
Bone is one of the most common sites of metastasis in patients with advanced breast cancer; however, the mechanisms of bone metastasis remain to be fully elucidated. Animal models are essential research tools for investigating the mechanisms of diseases and drug actions. To date, there have only been a few reports in which C57BL/6 mice were used for the study of bone metastases of breast cancer. In the current study, we found that intracardiac inoculation of C57BL/6 mouse-derived parental E0771 breast cancer cells (E0771/Pa) frequently lead to bone metastases in C57BL/6 mice within 2 weeks...
April 17, 2018: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/29650917/-a-case-of-primary-spinddle-cell-carcinoma-of-the-breast
#16
Hiroshi Kawai, Chihiro Yoshikawa, Kento Kawasaki, Norichika Iga, Ryosuke Yoshida, Naohisa Waki, Futoshi Uno, Masahiro Ishizaki, Hideyuki Nishi, Kazuki Yamashita, Shinichiro Miyoshi
A 76-year-old female underwent breast-conserving surgery of the right breast and sentinel lymph node biopsy for primary breast cancer. Three years later, mammography and ultrasonography showed a small nodule in the right breast. There was nothing abnormal in the left breast. Three months later, she complained of a huge and rapid growing mass in the left breast. Malignant cells were obtained on fine needle aspiration biopsy in the right breast tumor. But it was not possible to diagnose whether the left breast tumor was benign or malignant on fine needle aspiration biopsy and needle biopsy...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29627288/multiparametric-whole-body-mri-with-diffusion-weighted-imaging-and-adc-mapping-for-the-identification-of-visceral-and-osseous-metastases-from-solid-tumors
#17
Michael A Jacobs, Katarzyna J Macura, Atif Zaheer, Emmanuel S Antonarakis, Vered Stearns, Antonio C Wolff, Thorsten Feiweier, Ihab R Kamel, Richard L Wahl, Li Pan
RATIONALE AND OBJECTIVES: The purpose of this study was to investigate the use of multiparametric, whole-body, diffusion-weighted imaging (WB-DWI) and apparent diffusion coefficient (ADC) maps with T2 -weighted magnetic resonance imaging (MRI) at 3T for the detection and monitoring of metastatic disease in patients. MATERIALS AND METHODS: Fifty-four participants (32 healthy subjects and 22 patients) were scanned with WB-DWI methods using a 3T MRI scanner. Axial, sagittal, or coronal fat-suppressed T2 -weighted (T2 WI), T1 -weighted (T1 WI), and DWI images were acquired...
April 4, 2018: Academic Radiology
https://www.readbyqxmd.com/read/29611757/experience-with-eribulin-in-patients-with-metastatic-breast-cancer-and-associated-hepatic-impairment-case-studies
#18
Daniel Acosta-Eyzaguirre, Isabel Calvo Plaza, Antonia Perelló Martorell, Elena Hernández Agudo, Laura García-Estévez
Hepatic impairment in breast cancer arises from metastatic spread of tumor cells to the liver and signals a poor prognosis. Systemic therapy is the mainstay of treatment. Three women with hepatic dysfunction secondary to breast cancer who were treated with eribulin are presented herein. In the first case, third-line eribulin at the time of acute liver failure due to metastases maintained response for up to 9 months with good tolerability. In the second case, a woman with secondary bone and liver disease had progression-free survival of 5 months to third-line eribulin and, upon rechallenge after a drug holiday, had almost four more months of stable disease...
March 2018: Future Oncology
https://www.readbyqxmd.com/read/29604436/investigational-chemotherapy-and-novel-pharmacokinetic-mechanisms-for-the-treatment-of-breast-cancer-brain-metastases
#19
REVIEW
Neal Shah, Afroz S Mohammad, Pushkar Saralkar, Samuel A Sprowls, Schuyler D Vickers, Devin John, Rachel M Tallman, Brandon Lucke-Wold, Katherine E Jarrell, Mark Pinti, Richard L Nolan, Paul R Lockman
In women, breast cancer is the most common cancer diagnosis and second most common cause of cancer death. More than half of breast cancer patients will develop metastases to the bone, liver, lung, or brain. Breast cancer brain metastases (BCBM) confers a poor prognosis, as current therapeutic options of surgery, radiation, and chemotherapy rarely significantly extend life and are considered palliative. Within the realm of chemotherapy, the last decade has seen an explosion of novel chemotherapeutics involving targeting agents and unique dosage forms...
March 28, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29603079/effects-of-breast-and-prostate-cancer-metastases-on-lumbar-spine-biomechanics-rapid-in-silico-evaluation
#20
J Lorkowski, O Grzegorowska, M S Kozień, I Kotela
Metastases to distant organs are a frequent occurrence in cancer diseases. The skeletal system, especially the spine, is one such organ. The objective of this study was to apply a numerical modeling, using a finite element method (FEM), for the evaluation of deformation and stress in lumbar spine in bone metastases to the spine. We investigated 20 patients (10 women and 10 men) aged 38-81 years. In women, osteolytic lesions in lumbar spine accompanied breast cancer, in men it was prostate cancer. Geometry of FEM models were built based on CT scans of metastatic lumbar spine...
March 31, 2018: Advances in Experimental Medicine and Biology
keyword
keyword
61124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"